The Experts below are selected from a list of 156 Experts worldwide ranked by ideXlab platform
Bridgette D. Semple - One of the best experts on this subject based on the ideXlab platform.
-
corrigendum to acute treatment with trkb agonist lm22a 4 confers neuroprotection and preserves myelin integrity in a mouse model of pediatric traumatic brain injury Experimental Neurology 339 2021 113652
Experimental Neurology, 2021Co-Authors: Jessica L Fletcher, Larissa K Dill, Rhiannon J Wood, Sharon Wang, Kate Robertson, Simon S Murray, Akram Zamani, Bridgette D. SempleAbstract:The authors regret the inclusion of a calculation error, in results section 3.6 (Fig. 5a and b), regarding cortical and hippocampal tissue volumes. This calculation error affected all data equally (actual values are 10-fold higher than reported), such that statistical analyses and interpretations remain accurate. The correct version of the figure is provided below. [Figure presented] The authors would like to apologise for any inconvenience caused.
-
Early preservation of mitochondrial bioenergetics supports both structural and functional recovery after neurotrauma.
Experimental Neurology, 2014Co-Authors: Bridgette D. SempleAbstract:N-acetylcysteine, a precursor to the potent antioxidant glutathione, has been investigated as a potential therapeutic agent for several decades; however, inconsistent efficacy has been reported for diseases of the central nervous system, postulated to result from restricted passage of this molecule across the blood-brain/spinal cord barriers and cellular membranes, resulting in low bioavailability. The amide form of N-acetylcysteine (NACA) overcomes these limitations while maintaining a high antioxidant potential, and shows promise for combating secondary pathogenesis attributed to oxidative stress. Neurotrauma precipitates a rapid and prolonged disruption of mitochondrial bioenergetics, whereby the production of reactive oxygen species overwhelms the endogenous antioxidant capacity of the cells. Two noteworthy papers from collaborative teams have recently been published in Experimental Neurology, in which NACA was applied to rodent models of traumatic brain and spinal cord injury, respectively. Using sensitive methods to measure respiratory rates in isolated mitochondrial populations, treatment with NACA was shown to maintain mitochondrial function and boost antioxidant reserves, which corresponded with improvements in structural and functional outcomes in both studies. This commentary aims to highlight key findings from this research in a broader context, with an emphasis on methodological advances, future research possibilities, and potential applicability to brain and/or spinal cord injured patients.
Phillip G. Popovich - One of the best experts on this subject based on the ideXlab platform.
-
Corrigendum to "The paradox of chronic neuroinflammation, systemic immune suppression, autoimmunity after traumatic chronic spinal cord injury" (Experimental Neurology 258 (2014) 121-129)
Experimental Neurology, 2014Co-Authors: Jan M. Schwab, Yi Zhang, Marcel A. Kopp, Benedikt Brommer, Phillip G. PopovichAbstract:a Department of Neurology and Experimental Neurology, Clinical and Experimental Spinal Cord Injury Research (Neuroparaplegiology), Charite-Universitatsmedizin Berlin, D-10117 Berlin, Germany b Spinal Cord Injury Center, Trauma Hospital Berlin, D-12683 Berlin, Germany c Center for Brain and Spinal Cord Repair, Department of Neuroscience, Wexner Medical Center, The Ohio State University Medical Center, Columbus, OH 43210, USA
-
Replication and reproducibility in spinal cord injury research.
Experimental Neurology, 2012Co-Authors: Oswald Steward, Phillip G. Popovich, W. Dalton Dietrich, Naomi KleitmanAbstract:This special issue of Experimental Neurology compiles a series of papers that either explicitly replicate published studies or retest phenomena reported in previous publications. The explicit replications were carried out as part of the "Facilities of Research Excellence-Spinal Cord Injury" (FORE-SCI) program launched by the National Institute of Neurological Disorders and Stroke (NINDS) in 2003. Here, we review the FORE-SCI replication experiments published prior to those in this special issue. We then discuss emerging issues regarding replication and reproducibility in spinal cord injury research, especially in terms of potential translation to clinical trials.
Ralf Gold - One of the best experts on this subject based on the ideXlab platform.
-
disease activity during pregnancy after fingolimod withdrawal due to planning a pregnancy in women with multiple sclerosis p5 032
Neurology, 2018Co-Authors: Spalmai Hemat, Maria K Houtchens, Angela Vidaljordana, Michael Guger, Doriana Landi, Miguel Dhaeseleer, Pietro Annovazzi, Mar Tintore, Sandra Thiel, Ralf GoldAbstract:Objective: To determine the relapse and disability risk at the end of pregnancy in women with Multiple Sclerosis (MS) who stopped fingolimod (FTY) for pregnancy planning versus those who stopped FTY once pregnancy was established. Background: The magnitude of the relapse risk after FTY withdrawal in women with MS planning a pregnancy is unknown but severe return of disease activity was described. Design/Methods: Pregnancies were prospectively collected in the German MS and pregnancy registry and by six international collaborators up to September 2017. Detailed information on course of MS, pregnancy, relapses and outcome of pregnancy was obtained. Results: We analyzed 139 pregnancies divided into group A: FTY stopped > 2 months prior to the last menstrual period (LMP) (n=35) (median interval between last FTY and LMP: 328 days (range 61–312)) and group B (n=104): exposed to FTY (median exposure of 38,6 days (1–123)) from LMP. 8 pregnancies are still ongoing. Of 35 women in group A, 10 (28,6%) experienced a relapse before pregnancy. After conception, in group A 13 (37,1%) women had 16 relapses during the three trimesters (7-7-2 according to trimester) compared to 25 (24%) women of group B (33 total: 9-14-10 according to trimester). Information on disability is available for 32/38 women (12 (92,3%) of group A and 20 (80%) group B) relapsing during pregnancy: in group A 5 (14,3%) women experienced a median EDSS worsening from 0.8 (0–2) to 2,7 (2–3,5); in group B 12 (11,5%) women experienced a median EDSS worsening from 1,95 (0–4) to 3,33 (2–4,5). Differences were not statistically significant for both outcomes. Conclusions: Despite the natural protection of pregnancy, a substantial group of women will experience a relapse during pregnancy with disability accumulation in some of the women. Disclosure: Dr. Hemat has nothing to disclose. Dr. Houtchens has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genzyme Sanofi, Teva Neurosciences, Biogen, Genentech. Dr. Vidal-Jordana has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis, Roche, and Sanofi-Aventis. Dr. Guger has nothing to disclose. Dr. Landi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme, Teva. Dr. D9Haeseleer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme, Teva. Dr. Annovazzi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis, Merck Serono, Genzyme, Biogen and Teva. Dr. Tintore has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer Schering Pharma, Merck-Serono, Biogen-Idec, Teva Pharmaceuticals, Sanofi-Aventis, Novartis, Almirall, Genzyme, and Roche. Dr. Thiel has nothing to disclose. Dr. Gold has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, and Novartis. Dr. Gold has received personal compensation in an editorial capacity for Therapeutic Advances in Neurological Diseases, Experimental Neurology and the Journal of Neuroimmunology. Dr. Gold has received research support from Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, Genzyme, Merck Serono, and Novartis. Dr. Hellwig has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with speaker honoraria: Biogen Idec, Teva, Sanofi Aventis, Novartis, Bayer Healthcare, Merck Serono.
-
safety and efficacy of long term treatment with daclizumab beta 6 year results from the selected extension study p6 390
Neurology, 2018Co-Authors: Ralf Gold, Ernstwilhelm Radue, Gavin Giovannoni, Krzysztof Selmaj, Eva Havrdova, Xavier Montalban, Dusan Stefoski, Till Sprenger, Randy Robinson, Jonathan SmithAbstract:Objective: To report long-term safety and efficacy of daclizumab beta in participants with relapsing MS in SELECTED. Background: SELECTED (NCT01051349) was an open-label extension study evaluating daclizumab beta for up to 6 additional years in participants who completed SELECT (NCT00390221)/SELECTION (NCT00870740). A previous interim analysis of SELECTED showed that effects were maintained over 3 years of continuous treatment and adverse events (AEs) did not significantly increase over time. Design/Methods: Participants who completed 1–2 years of daclizumab beta treatment in SELECT/SELECTION were eligible to receive open-label daclizumab beta 150mg subcutaneous every 4 weeks for up to 6 more years in SELECTED. Efficacy outcomes were analyzed from first dose of daclizumab beta in SELECT/SELECTION. Results: 90% (410/455) of participants who completed SELECT/SELECTION enrolled in SELECTED. Mean (median) time on treatment in SELECTED was 40.2 (45.1;range:0–66) months. Yearly incidence of AEs in Years 1 through ≥5 was 60%, 60%, 57%, 56% and 51%, respectively. 87% of participants experienced an AE; 26% a serious AE excluding MS relapse. Most participants (75%) who experienced AEs had mild/moderate AEs. There were no deaths during the study. Incidence of transaminase elevations >5× upper limit of normal was 9% for ALT and 6% for AST. Adjusted annualized relapse rate remained stable and low through Week >336 (0.10 [95% CI 0.04–0.26]). Incidence of 24-week confirmed disability progression remained low (23.9%) with continuous treatment. New gadolinium-enhancing and new/newly enlarging T2 hyperintense lesions occurred at rates similar to the reduced rates in SELECT/SELECTION. The mean percentage change in whole brain volume was −0.77%, −0.57%, −0.32%, −0.40%, −0.26%, −0.55%, −0.33% and 0.33% for Years 1–8, respectively. Conclusions: These results extend those from a previous 3-year analysis of SELECTED and demonstrate that the favorable benefit/risk profile of daclizumab beta was sustained over up to ~8 years of treatment, with no new safety concerns identified. Study Supported by: Biogen (Cambridge, MA, USA) and AbbVie Inc. (Chicago, IL, USA) Disclosure: Dr. Gold has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, and Novartis. Dr. Gold has received personal compensation in an editorial capacity for Therapeutic Advances in Neurological Diseases, Experimental Neurology and the Journal of Neuroimmunology. Dr. Gold has received research support from Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, Genzyme, Merck Serono, and Novartis. Dr. Radue has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with speaker fees from Actelion, Basilea, Bayer HealthCare, Biogen, Merck Serono, and Novartis. Dr. Radue has received research support from research support from Actelion, Bayer HealthCare, Biogen, Merck Serono, and Novartis. Dr. Giovannoni has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Received compensation for participating on Advisory Boards in relation to clinical trial design, trial steering committees and data and safety monitoring committees from: Abbvie, Almirall, Atara Bio, Biogen, Sanofi-Genzyme, Genentech, GSK, Merck, Novartis. Dr. Giovannoni has received personal compensation in an editorial capacity for Elsevier as Editor of MSARDs. Dr. Giovannoni has received research support from Takeda. Dr. Selmaj has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Celgene, Novartis, Merck, Roche. Dr. Havrdova has nothing to disclose. Dr. Montalban has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Actelion, Bayer, Biogen, Celgene, Genzyme, Merck, Novartis, Oryzon, Roche, Sanofi and Teva Pharmaceutical. Dr. Stefoski has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with consulting fees from Acorda, Biogen, Serono, and Teva Neuroscience; speaker fees from Acorda, Biogen, Elan, EMD Serono, and Teva Neuroscience. Dr. Stefoski has received royalty, license fees, or contractual rights payments from royalty payments of licensed drug from Acorda. Dr. Stefoski has received research support from research support from Biogen, Novartis, Pfizer, and Serono. Dr. Sprenger has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Actelion, Novartis, Sanofi Genzyme, Electrocore, Merck, TEVA. Dr. Robinson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of AbbVie Inc. Dr. Robinson holds stock and/or stock options in Holds stock/stock options in AbbVie Inc. Dr. Smith has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with employee of Biogen. Dr. Smith holds stock and/or stock options in holds stock/stock options in Biogen. Dr. Parks has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Biogen. Dr. Parks holds stock and/or stock options in Holds stock/stock options in Biogen. Dr. Giannattasio has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with employee of Biogen. Dr. Giannattasio holds stock and/or stock options in holds stock/stock options in Biogen. Dr. Lima has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with former employee of Biogen.
Robert J. Morecraft - One of the best experts on this subject based on the ideXlab platform.
-
corrigendum to volumetric effects of motor cortex injury on recovery of dexterous movements Experimental Neurology 220 2009 90 108
Experimental Neurology, 2010Co-Authors: Warren G. Darling, Marc A. Pizzimenti, Diane L. Rotella, Clayton R. Peterson, Stephanie M. Hynes, Kathryn Solon, David W. Mcneal, Kimberly S Stilwellmorecraft, Robert J. MorecraftAbstract:a Department of Integrative Physiology, Motor Performance Laboratory, The University of Iowa, Iowa City, IA 52242, USA b Department of Anatomy and Cell Biology, Carver College of Medicine, The University of Iowa, Iowa City, IA 52242, USA c Division of Basic Biomedical Sciences, Laboratory of Neurological Sciences, The University of South Dakota, Sanford School of Medicine, Vermillion, SD 57069, USA
Jing Zhu - One of the best experts on this subject based on the ideXlab platform.
-
ethoxyquin prevents development of neuropathy in rodent models of diabetic peripheral neuropathy and hiv associated neuropathy s46 004
Neurology, 2014Co-Authors: Ahme Hoke, Nicole Reed, Jing ZhuAbstract:OBJECTIVE: Currently, there are no effective disease-modifying therapies for diabetic peripheral neuropathy (DPN) or human immunodeficiency virus (HIV)-associated sensory neuropathy (HIV-SN). We evaluated the impact of ethoxyquin on development of DPN and HIV-SN in rodent models. BACKGROUND: Recently, we identified ethoxyquin as potential neuroprotective compound to prevent distal axonal degeneration induced by paclitaxel. This study was carried out as a phenotypic drug screen and the molecular target of ethoxyquin was later identified as heat shock protein 90 (hsp90). In the current study, we evaluated the impact of daily administration of ethoxyquin on development of neuropathy in a rat model of type-1 diabetes and in a mouse model of HIV-SN. DESIGN/METHODS: Diabetes was induced in adult male Sprague-Dawley rats by injection of streptozotocin. After confirmation of fasting hyperglycemia, animals were given daily ethoxyquin and evaluated for presence of neuropathy serially and at the end of 2 months. In the mouse model of HIV-SN, transgenic mice expressing HIV envelope protein gp120 were given daily didanosine for 4 weeks to induce sensory neuropathy. Experimental group was co-administered daily ethoxyquin and both groups were evaluated for presence of neuropathy at the end of 4 weeks. In both the DPN and HIV-SN models, neuropathy was evaluated using sensory nerve conduction studies, thermal sensation evaluation using Hargreaves method, sural nerve morphometry and intraepidermal nerve fiber density using punch biopsies of the hind paws. RESULTS: Ethoxyquin partially prevented development of sensory neuropathy in both rodent models of DPN and HIV-SN using the intraepidermal nerve fiber density as a primary endpoint. CONSLUSIONS: This study extends the neuroprotective role that ethoxyquin plays in peripheral neuropathies to diabetic and HIV-associated neuropathies. Further development of ethoxyquin as a potential disease modifying therapy in peripheral neuropathies is warranted. Acknowledgement: This study was supported by the Foundation for Peripheral Neuropathy and Dr. Miriam and Sheldon Adelson Medical Research Foundation. Disclosure: Dr. Hoke has received personal compensation for activities with Unilab. Dr. Hoke has received personal compensation in an editorial capacity for Experimental Neurology. Dr. Hoke has received research support from Acorda Phamaceuticals. Dr. Reed has nothing to disclose. Dr. Zhu has nothing to disclose.
